Literature DB >> 29068547

Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40).

Daniel Alencar Rodrigues1,2, Pedro de Sena Murteira Pinheiro1,3, Thayssa Tavares da Silva Cunha Ferreira1,3, Sreekanth Thota1,4, Carlos Alberto Manssour Fraga1,2,3.   

Abstract

G-protein-coupled receptor 40 (GPR40) was recently identified as an interesting target for treatment of type 2 diabetes. The high level of expression in pancreatic beta cells and the dependence of glucose on stimulating the secretion of insulin led to great excitement in this field. The identification of this target was followed by the development of a series of agonists with great potential for the treatment of diabetes. All known agonists have the presence of a pharmacophoric carboxylic acid group in their structure, which makes several polar interactions at the binding site of this receptor. In this report, we provide a review of the structure-activity relationships of GPR40 agonists with a focus on the main strategies of medicinal chemistry used to develop each one of the main structural patterns exploited for this purpose. Additionally, we provide a general model for the design of GPR40 ligands that can help researchers to follow up some strategies and implement them in the development of novel agonists of this receptor.
© 2017 John Wiley & Sons A/S.

Entities:  

Keywords:  FFA1R; GPR40; GPR40 agonists; diabetes; free fatty acid receptor 1

Mesh:

Substances:

Year:  2017        PMID: 29068547     DOI: 10.1111/cbdd.13131

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  2 in total

1.  GPR40 Receptor Agonists for the Treatment of Type 2 Diabetes and Related Diseases.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2018-08-13       Impact factor: 4.345

Review 2.  Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus.

Authors:  Arpita Arora; Tapan Behl; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Sridevi Chigurupati; Rajwinder Kaur; Saurabh Bhatia; Ahmed Al-Harrasi; Celia Vargas-De-La-Cruz; Simona Bungau
Journal:  Inflammopharmacology       Date:  2021-10-20       Impact factor: 4.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.